Leaderboards/Endometrial and Cervical Cancer Treatments

Endometrial and Cervical Cancer Treatments

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Carrie Printz
Women's Health Initiative
2
Nicole Concin
Innsbruck Medical University
3
Lisa Vermij
Leiden University Medical Center
4
Magda Marečková
University of Oxford
5
Jindong Sheng
Tianjin Medical University Cancer Institute and Hospital
6
Sarah Volinsky-Fremond
Leiden University Medical Center
7
Eric Rios‐Doria
University of Washington
8
Natalia Galant
Medical University of Lublin
9
Holly Baker‐Rand
Musgrove Park Hospital
10
Ester P. Olthof
Netherlands Comprehensive Cancer Organisation

Papers

1
ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025
The Lancet Oncology|2025
191 cit.
2
An integrated single-cell reference atlas of the human endometrium
Nature Genetics|2024
144 cit.
3
Publication in Nature Medicine (2024) [88 citations, W4398769085]
Nature Medicine|2024
88 cit.
4
Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection
International Journal of Molecular Sciences|2024
81 cit.
5
Recent Advances in Endometrial Cancer Prevention, Early Diagnosis and Treatment
Cancers|2024
75 cit.
6
Diagnostic accuracy of MRI, CT, and [18F]FDG-PET-CT in detecting lymph node metastases in clinically early-stage cervical cancer — a nationwide Dutch cohort study
Insights into Imaging|2024
26 cit.
7
Variant Allele Frequency Analysis of Circulating Tumor DNA as a Promising Tool in Assessing the Effectiveness of Treatment in Non-Small Cell Lung Carcinoma Patients
Cancers|2024
15 cit.
8
Publication in Signal Transduction and Targeted Therapy (2025) [13 citations, W4412019553]
Signal Transduction and Targeted Therapy|2025
13 cit.
9
Prognosis of isolated tumor cells and use of molecular classification in early stage endometrioid endometrial cancer
International Journal of Gynecological Cancer|2024
9 cit.
10
Publication in Gynecologic Oncology (2024) [5 citations, W4402330480]
Gynecologic Oncology|2024
5 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Jose Alejandro Rauh‐Hain
The University of Texas MD Anderson Cancer Center
2
Aline Talhouk
University of British Columbia
3
Shaili Aggarwal
Drexel University
4
Angela D. Motter
National Comprehensive Cancer Network
5
Iulia Bârsan
Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș
6
Robert J. Grumbo
United States Department of the Army
7
Sara Espinosa
National Comprehensive Cancer Network
8
K Ochiai
Unknown
9
Sarah Chiang
Memorial Sloan Kettering Cancer Center
10
Gretchen Glaser
WinnMed

Papers

1
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network|2022
655 cit.
2
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network|2023
545 cit.
3
NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024
Journal of the National Comprehensive Cancer Network|2023
354 cit.
4
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024
Journal of the National Comprehensive Cancer Network|2024
125 cit.
5
Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network|2023
117 cit.
6
Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network|2024
84 cit.
7
Molecular-Based Immunohistochemical Algorithm for Uterine Leiomyosarcoma Diagnosis
Modern Pathology|2023
49 cit.
8
NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024
Journal of the National Comprehensive Cancer Network|2024
48 cit.
9
Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network|2025
31 cit.
10
Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol
International Journal of Gynecological Pathology|2022
29 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Carien L. Creutzberg
Leiden University Medical Center
2
Richard Pötter
Medical University of Vienna
3
Karl C. Podratz
Mayo Clinic
4
Nadeem R. Abu‐Rustum
Memorial Sloan Kettering Cancer Center
5
David G. Mutch
Cancer Research Center
6
Robert A. Soslow
Cleveland Clinic
7
Perry W. Grigsby
Washington University in St. Louis
8
Robert E. Scully
Ollscoil na Gaillimhe – University of Galway
9
Jessica N. McAlpine
University of British Columbia
10
Ie‐Ming Shih
Johns Hopkins University

Papers

1
Pelvic Radiation with Concurrent Chemotherapy Compared with Pelvic and Para-Aortic Radiation for High-Risk Cervical Cancer
New England Journal of Medicine|1999
2.3k cit.
2
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
International Journal of Gynecological Cancer|2020
1.9k cit.
3
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
The American Journal of Surgical Pathology|2010
1.8k cit.
4
Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial
The Lancet|2000
1.8k cit.
5
Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology
Radiotherapy and Oncology|2006
1.6k cit.
6
Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial
The Lancet|2010
1.1k cit.
7
Pelvic Irradiation With Concurrent Chemotherapy Versus Pelvic and Para-Aortic Irradiation for High-Risk Cervical Cancer: An Update of Radiation Therapy Oncology Group Trial (RTOG) 90-01
Journal of Clinical Oncology|2004
1k cit.
8
Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer
Cancer|2017
960 cit.
9
A clinically applicable molecular-based classification for endometrial cancers
British Journal of Cancer|2015
944 cit.
10
COX-2 is expressed in human pulmonary, colonic, and mammary tumors
Cancer|2000
872 cit.

Reagents for Endometrial and Cervical Cancer Treatments

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling Technology

FnCpf1/Cas12a (Strain U112) (E7I2B) Rabbit Monoclonal Antibody

#90111$161,351
View Evidence →
Agilent/Dako

p53 Tumor Suppressor Protein

#M7001
View Evidence →
Jackson ImmunoResearch

NOT AN ANTIBODY Peroxidase-Streptavidin

#016-030-084
View Evidence →

🌟 All-Time

Most validated

Agilent/DakoEvidence 63

Progesterone Receptor

Cited in 5 papers
#M3569
View Evidence →
ProteintechEvidence 64

PAX8 Polyclonal antibody

Cited in 5 papers
#10336-1-AP$449
View Evidence →
Cell Signaling TechnologyEvidence 65

Phospho-Rb (Ser807/811) (D20B12) Rabbit Monoclonal Antibody (Pacific Blue™ Conjugate)

#75864$493
View Evidence →